Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial
CONCLUSION: Anlotinib demonstrates its efficacy and safety in this phase ⅡB trial for the treatment of MTC and may become a new choice for this rare disease, especially for Chinese patients.PMID:33832949 | DOI:10.1158/1078-0432.CCR-20-2950
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Dapeng Li Yihebali Chi Xiaohong Chen Ming-Hua Ge Yuan Zhang Zhuming Guo Jun Wang Jie Chen Jiewu Zhang Ying Cheng Zhendong Li Hui Liu Jianwu Qin Jingqiang Zhu Ruochuan Cheng Zhengang Xu Xiangqian Zheng Pingzhang Tang Ming Gao Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | China Health | Proteinuria | Rare Diseases | Study | Thyroid | Thyroid Cancer